Siemens Healthineers earns CDC HoST-TT Certification for Total Testosterone Test
Siemens Healthineers' Atellica IM Testosterone II assay has received CDC HoSt-TT certification, ensuring high standards in total testosterone testing with ongoing performance since 2019, supporting clinical guidelines.
Siemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and Prevention (CDC) Hormone Standardization Program for Total Testosterone (HoSt-TT).
The Atellica IM TSTII assay, available on the Atellica IM and Atellica CI Analyzers, is the only fully automated immunoassay with CDC HoSt-TT certification, which it has maintained continuously since 2019. An evaluation of the assay’s performance was recently published in The Journal of Clinical Endocrinology & Metabolism.
Certification through the HoSt-TT program ensures traceability, minimizes variability, and supports compliance with Endocrine Society and American Urological Association guidelines. Ongoing certification ensures longitudinal consistency and reliable clinical interpretation of total testosterone results.
